Buy Rating Affirmed for Achieve Life Sciences on Strong Clinical Progress and Solid Financial Footing

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Achieve Life Sciences (ACHV – Research Report), with a price target of $30.00.

Michael Higgins has given his Buy rating due to a combination of factors regarding Achieve Life Sciences’ progress and prospects in developing cytisinicline, a plant-based alkaloid for smoking cessation. Higgins is encouraged by the positive outcomes from the Phase 3 trials, ORCA-2 and ORCA-3, as well as the ORCA-V1 Phase 2 trial, which have demonstrated the drug’s efficacy and safety among a significant number of nicotine-addicted smokers. The company’s innovative approach to address nicotine addiction in the American market, where approximately 34 million smokers are estimated, further underscores the potential for cytisinicline to meet a substantial unmet medical need.

The financial analyst’s optimism is further bolstered by the company’s robust financial position, with sufficient cash to fund operations into 2026, and the initiation of the Phase 3 ORCA-OL study. The high interest from clinical trial sites and patients, alongside the strategy to enroll previously treated cytisinicline patients, accelerates the path to New Drug Application (NDA) filing. The durable efficacy observed in Phase 3 patients, with a significant percentage remaining smoke or vape free, suggests a strong potential for long-term success of the treatment. Additionally, the efficient pace of re-enrollment based on past studies, and the readiness of trial sites, positions the company favorably for completing enrollment promptly and advancing towards regulatory submission.

Higgins covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Marinus, and Astria Therapeutics. According to TipRanks, Higgins has an average return of 3.3% and a 33.13% success rate on recommended stocks.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Achieve Life Sciences (ACHV) Company Description:

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.